Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
YH-306
Cat. No.:
0225LY-1097
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
YH-306 modulates the FAK signaling pathway to suppress the growth and metastasis of colorectal tumors.
Synonym:
YH306; TRV055 acetate (25849-90-5 Free base); 1373764-75-0; 2-(4-Hydroxyphenyl)-1-(1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-ethanone; 1-(3,4-Dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-(4-hydroxyphenyl)ethanone
CAS No.:
1373764-75-0
Compound CID:
60162063
Formula:
C19H18N2O2
Formula Weight:
306.36
Specification
Relative Density:
1.331 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
YH-306 can be used in oncology research to study the selective inhibition of the interaction between p53 and MDM2.
Library Information
Target:
Src; Rho; MMP; MMP; FAK; PI3K
Receptor:
FAK; c-Src; PI3K; Rac1; MMP-2; MMP-9
Pathways:
Cytoskeletal signaling; Angiogenesis; Cell cycle/Checkpoint; Proteases/Proteasome; PI3K/Akt/mTOR signaling; Tyrosine kinase/adaptors
Plate Number:
AOCL-15
Plate Location:
b3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
15 mg/mL; 48.96 mM
